Halogenated Insulin Analogues for Thermal Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Insulin analogues face challenges with thermal instability, leading to rapid degradation and fibrillation, especially in regions lacking consistent refrigeration, which complicates their storage, delivery, and use, particularly in the developing world, and there is a need for formulations that balance stability during storage with rapid absorption post-injection.
Innovation Solution
The development of insulin analogues with halogenated phenylalanine substitutions at positions B24, B25, or B26, such as chlorinated or fluorinated phenylalanine, which enhance thermal stability and resistance to fibrillation while maintaining biological activity, allowing for improved storage and rapid absorption profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If insulin analogues are stored at elevated temperatures, then thermal stability is improved, but biological activity is lost due to degradation and fibrillation
Solution Approach 1:
The patent applies parameter changes by substituting specific amino acid residues in insulin with halogenated variants (fluorinated, chlorinated, or brominated phenylalanine at positions B24, B25, or B26). This chemical modification changes the physical and chemical parameters of the insulin molecule, enhancing its thermal stability while preserving its biological activity through careful selection of substitution positions and halogen types.
Solution Approach 2:
The patent creates composite insulin analogues by combining the insulin peptide structure with halogenated phenylalanine residues. This composite approach integrates the stabilizing effects of halogen substitution into the insulin molecule, producing a hybrid structure that maintains both thermal resistance and biological functionality.
2Stability of the object's composition
If refrigeration is used to maintain insulin stability, then degradation is prevented, but storage and delivery complexity increases in regions lacking consistent electricity
Solution Approach 1:
The patent develops insulin analogues that are inherently stable at ambient temperatures without requiring refrigeration infrastructure. The halogenated insulin formulations can be stored as stable solids or in non-refrigerated liquid formulations, eliminating the need for complex cold chain storage systems and making them suitable for use in resource-limited settings.
3Speed
If insulin analogues are designed for rapid absorption, then post-injection efficacy is improved, but storage stability is reduced
Solution Approach 1:
The patent applies local quality by making site-specific substitutions at positions B24, B25, or B26 of the insulin B-chain. These localized modifications at specific residues allow the insulin analogue to achieve both rapid absorption characteristics and enhanced storage stability, as the halogen substitution at these particular positions provides thermal stability without compromising the structural features needed for rapid action.
Data Source
AI summary
An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine, ortho-monobromo-phenylalanine, ortho-monochloro-phenylalanine, or para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The halogenated insulin analogues retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. Halogen substitution-based stabilization of insulin may enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.